Cannabinoid-induced Fos expression within A10 dopaminergic neurons

Brain Research

Volumn 963, Issue 1-2, 2003, Pages 15-25

  Patel, Sachin ^a   Hillard, Cecilia J ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Cannabis; CB1 receptor; Clonidine; CP55940; Dopamine; Locus coeruleus; Marijuana; Prazosin; SR141716; Tyrosine hydroxylase

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ALPHA 1 ADRENERGIC RECEPTOR; CANNABINOID; CANNABINOID 1 RECEPTOR; CLONIDINE; PRAZOSIN; PROTEIN FOS; RIMONABANT;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; IMMUNOREACTIVITY; LOCUS CERULEUS; MALE; MOUSE; NEUROTRANSMISSION; NONHUMAN; NORADRENERGIC SYSTEM; PARABRACHIAL NUCLEUS; PRIORITY JOURNAL;

ADRENERGIC ALPHA-AGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; CANNABINOIDS; CEREBRAL CORTEX; CLONIDINE; CYCLOHEXANOLS; DOPAMINE; GENE EXPRESSION REGULATION; GENES, FOS; IMMUNOHISTOCHEMISTRY; LIMBIC SYSTEM; LOCUS COERULEUS; MALE; MICE; MICE, INBRED ICR; NEURONS; NOREPINEPHRINE; PRAZOSIN; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; SYNAPTIC TRANSMISSION;

EID: 0037435933     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(02)03797-6     Document Type: Article

References (59)

1. Adams I.B., Martin B.R. Cannabis: pharmacology and toxicology in animals and humans. Addiction. 91:1996;1585-1614.
2. Albanese A., Minciacchi D. Organization of the ascending projections from the ventral tegmental area: a multiple fluorescent retrograde tracer study in the rat. J. Comp. Neurol. 216:1983;406-420.
3. Bassareo V., De Luca M.A., Di Chiara G. Differential expression of motivational stimulus properties by dopamine in the nucleus accumbens shell versus core and prefrontal cortex. J. Neurosci. 22:2002;4709-4719.
4. Cheer J.F., Kendall D.A., Marsden C.A. Cannabinoid receptors and reward in the rat: a conditioned place preference study. Psychopharmacology (Berl.). 151:2000;25-30.
5. Cheer J.F., Marsden C.A., Kendall D.A., Mason R. Lack of response suppression follows repeated ventral tegmental cannabinoid administration: an in vitro electrophysiological study. Neuroscience. 99:2000;661-667.
6. Chen J., Marmur R., Pulles A., Paredes W., Gardner E.L. Ventral tegmental microinjection of delta 9-tetrahydrocannabinol enhances ventral tegmental somatodendritic dopamine levels but not forebrain dopamine levels: evidence for local neural action by marijuana's psychoactive ingredient. Brain Res. 621:1993;65-70.
7. Chen J., Paredes W., Gardner E.L. In vivo brain microdialysis studies of delta-9-tetrahydrocannabinol on presynaptic dopamine efflux in the nucleus accumbens of the lewis rat. Soc. Neurosci. Abstr. 15:1989;1096.
8. Chen J., Paredes W., Lowinson J.H., Gardner E.L. delta-9-Tetrahydrocannabinol enhances presynaptic dopamine efflux in the medial prefrontal cortex. Eur. J. Pharmacol. 190:1990;259-262.
9. 9-THC using a nonionic surfactant. J. Pharm. Pharmacol. 25:1973;345-349.
10. D'Souza D.C., Perry E., Wray Y., MacDougall L., Wilson A., Khan M., Oh S., Odonnell E., Krystal J.H. Cannabinoid-dopamine interactions and psychosis: Haloperidol effects in a cannabinoid model psychosis. International Symposium on Cannabinoids: 2001;127 International Cannabinoid Research Society, Madrid, Spain.
11. Dazzi L., Spiga F., Pira L., Ladu S., Vacca G., Rivano A., Jentsch J.D., Biggio G. Inhibition of stress- or anxiogenic-drug-induced increases in dopamine release in the rat prefrontal cortex by long-term treatment with antidepressant drugs. J. Neurochem. 76:2001;1212-1220.
12. Deutch A.Y., Lee M.C., Gillham M.H., Cameron D.A., Goldstein M., Iadarola M.J. Stress selectively increases fos protein in dopamine neurons innervating the prefrontal cortex. Cereb. Cortex. 1:1991;273-292.
13. Di Chiara G., Loddo P., Tanda G. Reciprocal changes in prefrontal and limbic dopamine responsiveness to aversive and rewarding stimuli after chronic mild stress: implications for the psychobiology of depression. Biol. Psychiatry. 46:1999;1624-1633.
14. Diana M., Melis M., Gessa G.L. Increase in meso-prefrontal dopaminergic activity after stimulation of CB1 receptors by cannabinoids. Eur. J. Neurosci. 10:1998;2825-2830.
15. Egertova M., Elphick M.R. Localisation of cannabinoid receptors in the rat brain using antibodies to the intracellular C-terminal tail of CB(1). J. Comp. Neurol. 422:2000;159-171.
16. Ettenberg A. Dopamine, neuroleptics, and reinforced behavior. Neurosci. Behav. Rev. 13:1989;105-111.
17. French E.D. delta9-Tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors. Neurosci. Lett. 226:1997;159-162.
18. French E.D., Dillon K., Wu X. Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. Neuroreport. 8:1997;649-652.
19. Gessa G.L., Melis M., Muntoni A.L., Diana M. Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors. Eur. J. Pharmacol. 341:1998;39-44.
20. Grenhoff J., Nisell M., Ferre S., Aston-Jones G., Svensson T.H. Noradrenergic modulation of midbrain dopamine cell firing elicited by stimulation of the locus coeruleus in the rat. J. Neural Transm. Gen. Sect. 93:1993;11-25.
21. Grenhoff J., Svensson T.H. Clonidine modulates dopamine cell firing in rat ventral tegmental area. Eur. J. Pharmacol. 165:1989;11-18.
22. Hall W., Degenhardt L. Cannabis use and psychosis: a review of clinical and epidemiological evidence. Aust. N.Z. J. Psychiatry. 34:2000;26-34.
23. Hall W., Solowij N. Long-term cannabis use and mental health. Br. J. Psychiatry. 171:1997;107-108.
24. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., DeCosta B.R., Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 11:1991;563-583.
25. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., DeCosta B.R., Rice K.C. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. USA. 87:1990;1932-1936.
26. Imperato A., Puglisi-Allegra S., Casolini P., Zocchi A., Angelucci L. Stress-induced enhancement of dopamine and acetylcholine release in limbic structures: role of corticosterone. Eur. J. Pharmacol. 165:1989;337-338.
27. Jentsch J.D., Andrusiak E., Tran A., Bowers M.B. Jr., Roth R.H. Delta 9-tetrahydrocannabinol increases prefrontal cortical catecholaminergic utilization and impairs spatial working memory in the rat: blockade of dopaminergic effects with HA966. Neuropsychopharmacology. 16:1997;426-432.
28. Jentsch J.D., Wise A., Katz Z., Roth R.H. Alpha-noradrenergic receptor modulation of the phencyclidine- and delta9-tetrahydrocannabinol-induced increases in dopamine utilization in rat prefrontal cortex. Synapse. 28:1998;21-26.
29. Jones B.E., Moore R.Y. Ascending projections of the locus coeruleus in the rat. II. Autoradiographic study. Brain Res. 127:1977;23-53.
30. Jones L.S., Gauger L.L., Davis J.N. Anatomy of brain alpha1-adrenergic receptors: in vitro autoradiography with [125I]HEAT. J. Comp. Neurol. 231:1985;190-208.
31. Kaplan H.I., Sadock B.J. Synopsis of Psychiatry. 8th Edition: 1997;Lippincott, Williams and Wilkins, Baltimore.
32. Kaplan H.S. Psychosis associated with marijuana. NY State J. Med. 71:1971;433-435.
33. Koob G.F. Drugs of abuse: anatomy, pharmacology, and function of reward pathways. Trends Pharmacol. Sci. 55:1992;9-14.
34. Koob G.F., Nestler E.J. The neurobiology of drug addiction. J. Neuropsychiatry Clin. Neurosci. 9:1997;482-497.
35. Kuster J., Stevenson J., Ward S., D'Ambra T., Haycock D. Aminoalkylindole binding in rat cerebellum: selective displacement by natural and synthetic cannabinoids. J. Pharmacol. Exp. Ther. 264:1993;1352-1363.
36. Lee A., Rosin D.L., Van Bockstaele E.J. Alpha2-adrenergic receptors in the rat nucleus locus coeruleus: subcellular localization in catecholaminergic dendrites, astrocytes, and presynaptic axon terminals. Brain Res. 795:1998;157-169.
37. Little P.J., Compton D.R., Johnson M.R., Melvin L.S., Martin B.R. Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. J. Pharmacol. Exp. Ther. 247:1988;1046-1051.
38. Maclean K., Littleton L.M. Environmental stress as a factor in the response of rat rat brain catecholamine metabolism to delta-8-tetrahydrocannabinol. Eur. J. Pharmacol. 41:1977;171-182.
39. Martellotta M.C., Cossu G., Fattore L., Gessa G.L., Fratta W. Self-administration of the cannabinoid receptor agonist WIN 55,212-2 in drug-naive mice. Neuroscience. 85:1998;327-330.
40. Matsuda L.A. Localization of cannabinoid receptor mRMA in the rat brain. J. Comp. Neurol. 327:1993;535-550.
41. Millan M.J., Lejeune F., Gobert A., Brocco M., Auclair A., Bosc C., Rivet J., Lacoste J., Cordi A., Dekeyne A. S18616, a highly potent spiromidazoline agonist at alpha2-adrenoceptors: II. Influence on monoaminergic transmission, motor function, and anxiety in comparison with dexmedetomidine and clonidine. J. Pharmacol. Exp. Ther. 295:2000;1206-1222.
42. Morgan J.I., Curran T. Role of ion influx in the control of c-fos expression. Nature. 322:1986;552-555.
43. Morgan J.I., Curran T. Calcium as a modulator of the immediate-early gene cascade in neurons. Cell Calcium. 9:1988;303-311.
44. Muntoni A., Pillolla G., Diana M., Pani L., Gessa G.L. The cannabinoid Win 55,212-2 stimulates locus coeruleus noradrenergic neurons in rats. International Symposium on Cannabinoids: 2001;51 International Cannabinoid Research Society, Madrid, Spain.
45. Murphy B.L., Arnsten A.F., Jentsch J.D., Roth R.H. Dopamine and spatial working memory in rats and monkeys: pharmacological reversal of stress-induced impairment. J. Neurosci. 16:1996;7768-7775.
46. Patel N.A., Moldow R.L., Patel J.A., Wu G., Chang S.L. Arachidonylethanolamide (AEA) activation of FOS proto-oncogene protein immunoreactivity in the rat brain. Brain Res. 797:1998;225-233.
47. Patel S., Hillard C.J. Cannabinoid cb(1) receptor agonists produce cerebellar dysfunction in mice. J. Pharmacol. Exp. Ther. 297:2001;629-637.
48. Paxinos G., Franklin K.B.J. The Mouse Brain in Stereotaxic Coordinates. 2nd Edition: 2001;Academic Press, San Diego, CA.
49. Phillipson O.T. Afferent projections to the ventral tegmental area of Tsai and interfascicular nucleus: a horseradish peroxidase study in the rat. J. Comp. Neurol. 187:1979;117-143.
50. Robbe D., Alonso G., Duchamp F., Bockaert J., Manzoni O.J. Localization and mechanisms of action of cannabinoid receptors at the glutamatergic synapses of the mouse nucleus accumbens. J. Neurosci. 21:2001;109-116.
51. Sanudo-Pena M.C., Tsou K., Delay E.R., Hohman A.G., Force M., Walker J.M. Endogenous cannabinoids as an aversive or counter-rewarding system in the rat. Neurosci. Lett. 223:1997;125-128.
52. Schultz W., Apicella P., Ljungberg T. Response of monkey dopamine neurons to reward and conditioned stimuli during successive steps of learning a delayed response task. J. Neurosci. 13:1993;900-913.
53. Schultz W., Dayan P., Montague P.R. A neural substrate of prediction and reward. Science. 275:1997;1593-1599.
54. Seeman P., Lee T., Chau-Wong M., Wong K. Antipsychotic drug dose and neuroleptic/dopamine receptors. Nature. 261:1976;717-719.
55. Tsou K., Brown S., Sanudo-Pena M.C., Mackie K., Walker J.M. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience. 83:1998;393-411.
56. Vaughan C.W., Connor M., Bagley E.E., Christie M.J. Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurons in vitro. Mol. Pharmacol. 57:2000;288-295.
57. Wise R.A. Neuroleptics and operant behavior: the anhedonia hypothesis. Behav. Brain Res. 5:1983;39-53.
58. Wise R.A. Drug-activation of brain reward pathways. Drug Alcohol Depend. 51:1998;13-22.
59. Yoshida M., Shirouzu M., Tanaka M., Semba K., Fibinger H.C. Dopaminergic neurons in the nucleus raphe dorsalis innervate the prefrontal cortex in the rat: a combined retrograde tracing and immunohistochemical study using anti-dopamine serum. Brain Res. 496:1989;373-376.